APLLTD - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.8
✅ Positive
APLLTD demonstrates strong revenue growth, reflected in a significant increase in quarterly profits and a robust ROE and ROCE. The company's debt-to-equity ratio is healthy, indicating financial stability and potential for future investment.
⚠️ Limitation
Despite positive recent earnings, the stock valuation remains relatively high compared to industry peers, and investor sentiment may be influenced by broader market fluctuations or sector-specific concerns. The reliance on a single product (Prucalopride) creates concentration risk.
📉 Company Negative News
None found
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is currently experiencing growth driven by increasing healthcare expenditure globally and the rising prevalence of chronic diseases, particularly in emerging markets. Companies focused on generics and specialty drugs are generally performing well due to favorable pricing dynamics and demand for innovative therapies.
🧾 Conclusion
Given the current price of 794 ₹ and a P/E ratio of 22.4, an entry zone around 750-765 ₹ offers potential upside as the company appears undervalued relative to its growth prospects. Long-term holding guidance suggests maintaining a position while monitoring quarterly earnings and industry trends for further catalysts. This stock represents a moderate investment opportunity with reasonable risk given the industry outlook and solid financial metrics.